Causes of @entity204 and subsequent treatment after initial radical or palliative therapy of stage III XXXX .

@entity1 @entity6220 @entity66 @entity5 @entity2 @entity1149 @entity204
INTRODUCTION: @entity5 is the most advanced stage of @entity2 for which radical (potentially curative) treatment is often discussed. Understanding the reasons for mortality and subsequent treatments in @entity1 with stage iii @entity1149 ( @entity1149 ) is important. METHODS: This retrospective cohort study extracted demographic, clinical, treatment, and outcomes data for @entity1 with newly diagnosed stage iii @entity1149 diagnosed between 1 January 2008 and 31 December 2012 at a single institution. RESULTS: The study included 237 @entity1 with stage iii @entity1149 , 130 of whom were not treated with radical or curative intent (55%). Median survival in the entire cohort was 14 months from diagnosis. For @entity1 treated with radical-intent therapy, causes of @entity204 varied with the time period. The hazard rate for @entity204 was approximately 2.8 per 100 @entity1 -months of follow-up over the entire disease course and was highest between 6 months and 24 months. Over the entire time period, local causes accounted for 29% of @entity204 ; systemic @entity6220 , for 25%; and brain metastases, for 14%. For @entity1 treated with palliative intent, the overwhelming cause of @entity204 was @entity66 or progression (56% of @entity204 ). Only 12% of @entity1 in the palliative treatment group who progressed received subsequent chemotherapy; 23% of @entity1 in the radical group who progressed received palliative chemotherapy. The most frequent subsequent treatment in both groups was radiation therapy. CONCLUSIONS: The eventual life-ending event in stage iii @entity1149 varied for the @entity1 who qualified for, and were treated with, radical or curative intent and for the @entity1 who received palliative-intent therapy. Utilization of systemic chemotherapy in @entity1 not fit for radical therapy is low.
